Fig. 4From: Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group studyEULAR response rates (full analysis set). EULAR response rates at weeks 52, 76 and 100. EULAR, European League Against RheumatismBack to article page